Steve Harr
CIK 1627387 · President & CEO · last filed 2026-03-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$21.77M
Companies
3
Total Filings
28
Lifetime Open-Market Net
-$5.19M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SANA | President & CEO | 8,124,070 | $2.68 | $21.77M | $0 | 8 | 2026-03-10 |
| Loxo Oncology, Inc. (LOXO) Delisted | Director | — | — | — | $0 | 4 | 2019-02-15 |
| Juno Therapeutics, Inc. (JUNO) Delisted | CFO & Head, Corp. Development | 97,152 | — | — | -$5.19M | 16 | 2018-03-07 |
Recent Filings · Page 2 of 3
28 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-03-07 | Juno Therapeutics, Inc. (JUNO) Delisted | Mixed | −639,517 | -$47.19M | EDGAR |
| 2018-03-01 | Juno Therapeutics, Inc. (JUNO) Delisted | Grant (A) | +11,544 | $0 | EDGAR |
| 2018-02-09 | Juno Therapeutics, Inc. (JUNO) Delisted | Mixed | −164,494 | -$145.7K | EDGAR |
| 2018-02-02 | Juno Therapeutics, Inc. (JUNO) Delisted | Grant (A) | +29,135 | $0 | EDGAR |
| 2017-12-22 | Juno Therapeutics, Inc. (JUNO) Delisted | Mixed | — | -$315.4K | EDGAR |
| 2017-10-20 | Juno Therapeutics, Inc. (JUNO) Delisted | Grant (A) | +35,893 | $0 | EDGAR |
| 2017-07-05 | Juno Therapeutics, Inc. (JUNO) Delisted | Mixed | — | -$186.2K | EDGAR |
| 2017-06-29 | Juno Therapeutics, Inc. (JUNO) Delisted | Mixed | — | -$186.2K | EDGAR |
| 2017-06-23 | Loxo Oncology, Inc. (LOXO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-02-09 | Juno Therapeutics, Inc. (JUNO) Delisted | Grant (A) | +27,439 | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.